Emerging glycobiology Target early-stage glycobiology researchers and labs expanding in glycan analysis by offering specialized tools, antibodies, and assay development services that align with GlycoScientific's iGlycoMab launch and focus on glycans.

Monoclonal antibody focus Position GlycoScientific’s iGlycoMab capabilities as a foothold for partnerships or co-development deals with pharma and biotech firms seeking glycan-labeled antibodies for research, diagnostics, or therapeutic development.

Small team agility Leverage the small team size to propose highly customized, fast-turnaround collaborations, contract research, and pilot projects that can scale into larger partnerships as revenue grows beyond the current 1–10 million range.

Biomarker and disease relevance Highlight opportunities around glycans as disease-associated biomarkers (cancer, diabetes, neurodegenerative, autoimmune) to approach translational research groups and contract opportunities in biomarker discovery and assay standardization.

Technology and ecosystem fit Align sales messaging with existing tech stack and channels (Shopify for merch, iCIMS for recruiting, analytics) to propose integrated solutions, training packages, and reproducible workflows that resonate with research labs building glycomics pipelines.